Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 60% of Japan Diabetes Patients Bear CV Risk Factors, or Suffered Event: Novo
July 16, 2019
- Simone Thomsen Tapped as Lilly Japan Chief; Patrik Jonsson to Take Big Job at HQ
July 12, 2019
- Ono Snags Stanford Spinout’s Macrophage Checkpoint in Asia
July 12, 2019
- PeptiStar’s Peptides Manufacturing Plant Completed
July 11, 2019
- Eisai Opens New Dementia Research Center in Cambridge
July 11, 2019
- Tarlige Most Promoted Drug for GPs in March: Anterio
July 11, 2019
- Astellas’ JAK Inhibitor Smyraf Now Available for RA
July 11, 2019
- Fujifilm, Axcelead Team Up for iPS Cell-Based Drug Discovery Support
July 11, 2019
- Takeda Releases App for IBD Patients; Sharing Info with Doctors
July 11, 2019
- Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
- Sumitomo Dainippon, NCGM Launch AMR Project in Vietnam
July 10, 2019
- Riona Shows Non-Inferiority vs. Ferromia in Iron Deficiency Anemia: JT/Torii
July 10, 2019
- Long-Term Efficacy, Safety Confirmed for Hemlibra: Roche/Chugai
July 10, 2019
- Large-Scale Study Unveils 14.7% of Ovarian Cancer Patients Carry BRCA Mutations in Japan: AstraZeneca
July 10, 2019
- Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
July 9, 2019
- Eisai, Dundee Univ. Ink Oncology Drug Discovery Deal
July 9, 2019
- Vortioxetine Hits Japan PIII Target for MDD: Takeda/Lundbeck
July 9, 2019
- Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
July 8, 2019
- Keytruda Retains Top Slot in Drug Sales Ranking in June: Encise Snapshot
July 8, 2019
- Japan Ethical Drug Sales Down 3.8% in May Due to Holidays: Crecon
July 8, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…